A shorter psychedelic treatment session could change how clinics approach depression care, provided meaningful benefits outlast the immediate drug experience. A randomized clinical trial published in JAMA offers encouraging evidence for intranasal 5-MeO-DMT, while leaving important questions about its eventual clinical role.
The findings bring two priorities into focus: reducing depressive symptoms and making supervised treatment more practical. Neither alone establishes whether a new intervention will work in everyday care.
The Challenge Of Delivering Psychedelic Care
For patients whose depression persists through multiple treatments, another intervention must offer more than a different mechanism. Its delivery requirements also matter.
Repeated appointments can complicate access, while prolonged psychedelic sessions place demands on clinical staff, treatment rooms, and patients’ schedules. A shorter experience could ease those pressures, but convenience must be evaluated alongside effectiveness, safety, and continued support.
Intranasal 5-MeO-DMT Enters A Controlled Test
The phase 2b study analyzed 193 adults across 38 sites. Participants had depression that had not responded to two to five antidepressant trials. They received one nasal dose of mebufotenin benzoate, a formulation of 5-MeO-DMT, at 8 mg, 12 mg, or a low comparator dose of 0.3 mg, alongside psychological support.
At day 29, the 12-mg group’s depression scores improved by an adjusted 5.3 points more than the comparator on the Montgomery-Åsberg Depression Rating Scale. The 8-mg group also showed a significant benefit. Differences persisted through day 57.
Most adverse events were mild or moderate, although one participant receiving 12 mg experienced two severe panic attacks.
Why The Comparison Matters
Random assignment makes this evidence more informative than improvement observed without a comparison group. Depression symptoms can change through time, expectations, supportive contact, and other influences.
However, a low-dose comparator cannot fully resolve the challenge of masking a noticeable psychedelic experience. Participants and clinicians showed substantial unblinding, although independent depression raters remained better blinded.
That distinction matters because keeping outcome assessors unaware of treatment assignment helps protect measurements, but cannot eliminate every influence of expectations.
A Shorter Recovery Needs Careful Interpretation
Most active-dose participants met discharge-readiness criteria within two hours. Actual discharge was permitted only after four hours.
Readiness is therefore a useful operational signal, rather than evidence that two-hour appointments are already established. Clinics would still need to account for preparation, monitoring, unexpected distress, recovery, and follow-up.
The distinction also prevents a common misunderstanding: a brief drug experience does not automatically mean a brief overall course of care.
Serotonin Biology Offers Clues, Not A Complete Explanation
Separate laboratory research published in Nature helps explain scientific interest in this compound. Researchers examined how 5-MeO-DMT and related molecules interact with serotonin receptors, including 5-HT1A and 5-HT2A, using structural imaging, cellular experiments, and mouse models.
These receptors act as molecular signaling targets. Understanding how a compound engages them can help researchers investigate which biological actions contribute to particular effects.
However, receptor activity does not establish why individual patients improve. The Nature research supplies mechanistic context, while the depression trial measures clinical outcomes. Connecting those levels of evidence requires further investigation.
Clinical Promise Extends Beyond Appointment Length
For psychiatrists and practice leaders, the central question is whether a manageable treatment session can produce reliable benefits that justify its staffing and support requirements.
This study brings symptom outcomes and recovery logistics into the same evaluation. It does not establish superiority over existing treatments, determine long-term maintenance needs, or demonstrate how the intervention would perform across a broader clinical population.
For patients, the practical implication is similarly measured: encouraging trial results are a step toward evaluating another option, rather than a basis for changing treatment independently.
The Next Test Is Reliable Benefit
Intranasal 5-MeO-DMT has produced a credible signal that warrants further controlled investigation. Future studies need to clarify who benefits, how durable those benefits are, and what additional treatment may be needed.
Its potential rests on a demanding combination: sustained symptom improvement, an acceptable safety profile, and a delivery model that remains workable beyond specialized research settings.
Citations
- Feifel D, Seynaeve M, Cubała WJ, et al. Single Intranasal Administration Of The Psychedelic Mebufotenin For Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA. Published October 26, 2026.
- Warren AL, Lankri D, Cunningham MJ, et al. Structural Pharmacology And Therapeutic Potential Of 5-Methoxytryptamines. Nature. 2024.
Explore more at Interventional Psychiatry Network.
